glp 1 agonist wiki Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Agonists For Obesity In
Description
doi: 10.2337/dc12-2454 217 ReuschJStewartMWPerkinsCMCirkelDTYeJPerryCRet al
In a study of 80 obese people with type 2 diabetes receiving semaglutide and dulaglutide, a 20% reduction in the thickness of EAT was observed (62) One meta-analysis demonstrated the cardioprotective effects of GLP-1 RAs, showing reductions in blood pressure and lipid profile, with a significant increase in HDL levels (63)
Trial participants were also regularly checked and evaluated by doctors to ensure the optimal treatment to reach treatment targets, which was not present in our cohort
10.2337/diab.24.11.1020
Curr Issues Mol Biol 2022;44:3465-80.ArticlePubMedPMC 41
